Medpace (NASDAQ:MEDP) Now Covered by Analysts at TD Cowen

TD Cowen began coverage on shares of Medpace (NASDAQ:MEDPFree Report) in a research report sent to investors on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $452.00 price target on the stock.

A number of other brokerages have also commented on MEDP. Guggenheim lifted their price objective on Medpace from $453.00 to $464.00 and gave the stock a buy rating in a research report on Wednesday, April 24th. StockNews.com upgraded Medpace from a hold rating to a buy rating in a research report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a research report on Monday, March 18th. They issued a hold rating and a $395.00 price objective for the company. Robert W. Baird boosted their target price on Medpace from $446.00 to $454.00 and gave the stock an outperform rating in a research report on Wednesday, April 24th. Finally, UBS Group raised Medpace from a neutral rating to a buy rating and upped their price target for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Medpace has a consensus rating of Moderate Buy and a consensus price target of $443.14.

Read Our Latest Analysis on Medpace

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $386.34 on Wednesday. Medpace has a twelve month low of $202.02 and a twelve month high of $421.00. The firm has a market cap of $11.97 billion, a PE ratio of 39.38, a price-to-earnings-growth ratio of 1.91 and a beta of 1.40. The business has a fifty day moving average of $394.11 and a 200-day moving average of $350.06.

Medpace (NASDAQ:MEDPGet Free Report) last announced its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company’s revenue was up 17.7% on a year-over-year basis. During the same period last year, the company earned $2.27 earnings per share. On average, analysts anticipate that Medpace will post 11.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle sold 5,695 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the completion of the transaction, the chief executive officer now owns 654,656 shares of the company’s stock, valued at approximately $258,909,901.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Medpace news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO August J. Troendle sold 5,695 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total value of $2,252,315.55. Following the completion of the sale, the chief executive officer now directly owns 654,656 shares of the company’s stock, valued at approximately $258,909,901.44. The disclosure for this sale can be found here. Insiders sold a total of 154,973 shares of company stock valued at $63,476,175 in the last quarter. 20.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medpace

Several large investors have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI boosted its holdings in shares of Medpace by 40.3% in the 1st quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock valued at $41,000 after buying an additional 29 shares during the last quarter. Miller Howard Investments Inc. NY boosted its holdings in shares of Medpace by 1.3% in the 4th quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after buying an additional 39 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Medpace by 5.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock valued at $316,000 after buying an additional 39 shares during the last quarter. Schulhoff & Co. Inc. boosted its holdings in shares of Medpace by 2.0% in the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock valued at $545,000 after buying an additional 45 shares during the last quarter. Finally, Coldstream Capital Management Inc. raised its stake in Medpace by 5.0% in the 4th quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock valued at $292,000 after acquiring an additional 45 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

(Get Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Articles

Analyst Recommendations for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.